Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widder’s departure was part of an executive succession plan
Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widders departure was part of an executive succession plan that the company has been considering for some time. MBI has not named Widders replacement.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.